Gain Therapeutics Inc
GANX
Market Cap$51.09M
Close$
$0.70
77.1% downside
Current Fair Value
77.1% downsideOvervalued by 77.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $51.09 Million |
|---|---|
| Enterprise Value | $35.32 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.71 |
| Beta | 1.05 |
| Outstanding Shares | 16,219,709 |
| Avg 30 Day Volume | 112,148 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.29 |
|---|---|
| PEG | -216.66 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 640.17 |
| Enterprise Value to EBIT | -1.59 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
ESG Score
No data
About Gain Therapeutics Inc
16 employeesGain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...